Alnylam Pharmaceuticals, IncAlnylam Pharmaceuticals, IncAlnylam Pharmaceuticals, Inc

Alnylam Pharmaceuticals, Inc

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪48.12 B‬CHF
−1.957CHF
‪−252.62 M‬CHF
‪2.04 B‬CHF
‪125.50 M‬
Beta (1Y)
1.13
Employees (FY)
‪2.23 K‬
Change (1Y)
+130 +6.19%
Revenue / Employee (1Y)
‪915.63 K‬CHF
Net income / Employee (1Y)
‪−113.28 K‬CHF

About Alnylam Pharmaceuticals, Inc.


CEO
Yvonne L. Greenstreet
Headquarters
Cambridge
Founded
2002
ISIN
US02043Q1076
FIGI
BBG00LVD60G6
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Check out other big names from the same industry as DUL.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
VTI
Vanguard Total Stock Market ETF
Weight
0.09%
Market value
‪1.83 B‬
USD
VO
Vanguard Mid-Cap ETF
Weight
0.65%
Market value
‪1.30 B‬
USD
VUG
Vanguard Growth ETF
Weight
0.20%
Market value
‪670.49 M‬
USD
VXF
Vanguard Extended Market ETF
Weight
0.75%
Market value
‪624.46 M‬
USD
VOT
Vanguard Mid-Cap Growth ETF
Weight
1.51%
Market value
‪487.47 M‬
USD
IWP
iShares Russell Mid-Cap Growth ETF
Weight
1.86%
Market value
‪386.32 M‬
USD
IBB
iShares Biotechnology ETF
Weight
5.49%
Market value
‪340.22 M‬
USD
CGGR
Capital Group Growth ETF
Weight
1.50%
Market value
‪252.92 M‬
USD
IWF
iShares Russell 1000 Growth ETF
Weight
0.18%
Market value
‪222.96 M‬
USD
IWR
iShares Russell Midcap ETF
Weight
0.46%
Market value
‪205.27 M‬
USD
VHT
Vanguard Health Care ETF
Weight
1.00%
Market value
‪175.92 M‬
USD

Explore more ETFs 

Curated watchlists where DUL is featured.

Frequently Asked Questions


The current price of DUL is 366.607 CHF — it has increased by 5.40% in the past 24 hours. Watch Alnylam Pharmaceuticals, Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange Alnylam Pharmaceuticals, Inc stocks are traded under the ticker DUL.
We've gathered analysts' opinions on Alnylam Pharmaceuticals, Inc future price: according to them, DUL price has a max estimate of 453.50 CHF and a min estimate of 258.57 CHF. Watch DUL chart and read a more detailed Alnylam Pharmaceuticals, Inc stock forecast: see what analysts think of Alnylam Pharmaceuticals, Inc and suggest that you do with its stocks.
DUL reached its all-time high on Aug 19, 2025 with the price of 366.607 CHF, and its all-time low was 132.022 CHF and was reached on Apr 24, 2024. View more price dynamics on DUL chart.
See other stocks reaching their highest and lowest prices.
DUL stock is 5.13% volatile and has beta coefficient of 1.13. Track Alnylam Pharmaceuticals, Inc stock price on the chart and check out the list of the most volatile stocks — is Alnylam Pharmaceuticals, Inc there?
Today Alnylam Pharmaceuticals, Inc has the market capitalization of ‪48.12 B‬, it has increased by 6.17% over the last week.
Yes, you can track Alnylam Pharmaceuticals, Inc financials in yearly and quarterly reports right on TradingView.
Alnylam Pharmaceuticals, Inc is going to release the next earnings report on Oct 23, 2025. Keep track of upcoming events with our Earnings Calendar.
DUL earnings for the last quarter are −0.40 CHF per share, whereas the estimation was −0.43 CHF resulting in a 6.20% surprise. The estimated earnings for the next quarter are 0.36 CHF per share. See more details about Alnylam Pharmaceuticals, Inc earnings.
Alnylam Pharmaceuticals, Inc revenue for the last quarter amounts to ‪613.84 M‬ CHF, despite the estimated figure of ‪525.92 M‬ CHF. In the next quarter, revenue is expected to reach ‪741.51 M‬ CHF.
DUL net income for the last quarter is ‪−52.58 M‬ CHF, while the quarter before that showed ‪−50.88 M‬ CHF of net income which accounts for −3.34% change. Track more Alnylam Pharmaceuticals, Inc financial stats to get the full picture.
No, DUL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 9, 2025, the company has ‪2.23 K‬ employees. See our rating of the largest employees — is Alnylam Pharmaceuticals, Inc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Alnylam Pharmaceuticals, Inc EBITDA is ‪−98.13 M‬ CHF, and current EBITDA margin is −5.35%. See more stats in Alnylam Pharmaceuticals, Inc financial statements.
Like other stocks, DUL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Alnylam Pharmaceuticals, Inc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Alnylam Pharmaceuticals, Inc technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Alnylam Pharmaceuticals, Inc stock shows the strong buy signal. See more of Alnylam Pharmaceuticals, Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.